INDEPENDENT LIMITED ASSURANCE REPORT

To: The Directors of AstraZeneca Plc

Introduction and objectives of work

Bureau Veritas UK Limited ("Bureau Veritas") has been engaged by AstraZeneca Plc ("AstraZeneca") to provide limited assurance over sustainability activities reported in the *AstraZeneca Annual Report and form 20-F Information 2022 (the "Report")*. The objective is to provide assurance to AstraZeneca and its stakeholders over the accuracy and reliability of the reported information and data. This Assurance Report applies to the related information included within the scope of work described below.

Scope of work

Subject to the below exclusions, the scope of our work was limited assurance over select information included within the following sections of the 'Report' for the period 1 January to the 31 December 2022 (the "Selected Information''):

- All text and data under Commitment to Society;
- Bioethics: all text and data under Clinical trial transparency, Research use of human biological samples and genomic information and Animals in research;
- Healthcare in low-and-middle-income countries: all text and data;
- Responsible sales and marketing: all text and data;
- Anti-bribery and corruption: all text and data;
- Operations: all text and data under Responsible Supply Chain;
- People and Sustainability: all text and data under Performance indicators: People and Performance Indicators: Sustainability;
- Human Rights: all text and data;
- Employee relations: all text and data;
- Workforce safety and health: all text and data;
- Sustainability strategy: all text and data;
- Access to healthcare: all text and data, including Achievements 2022, Equitable access, Diversity in clinical trials, Rare diseases, Covid-19 vaccine, Improving access to digital solutions, Affordability and pricing, Health system resilience, Partnership for Health System Resilience (PHSSR), Healthy Heart Africa Programme, Young Health Programme, Community investment, Product donation programmes;
- Environmental Protection: all text and data, including Achievements in 2022, Ambition Zero Carbon, Product Sustainability, Natural resources, Circular economy, Water stewardship, AZ Forest;
- Ethics and transparency: all text and data under Achievements in 2022 and Code of Ethics;
- EU Taxonomy: all text and data under Assessment, Revenue, Capital expenditure, Operating expenditure and Taxonomy eligibility and alignment [2021 and 2022 data];
- Taskforce on Climate-related Financial Disclosures Summary Statement and
- Sustainability Supplementary Information: all text and data under Greenhouse Gas (GHG) reporting.

Reporting Criteria

The Selected Information has been prepared in accordance with internal definitions set by AstraZeneca in their sustainability strategy and the One SHE Procedure – Safety, Health & Environment Reporting document. Where relevant, internal definitions draw on externally available guidelines such as the Global Reporting Initiative and should also be read and understood together with the following external documents: AZ Standard Safety, Health and Environment as set out at https://www.astrazeneca.com/content/dam/az/our-company/Documents/Safety-health-and-the-environment.pdf and Expectations of Third Parties as set out at https://www.astrazeneca.com/content/dam/az/PDF/Sustainability/Expectations-of-Third-Parties.pdf.

The definitions for AstraZeneca's GHG reporting are aligned with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard (revised edition), as set out in the "Greenhouse gas (GHG) reporting section of the Report.

The EU Taxonomy section is reported according to the EU Taxonomy Regulation (EU 2020/852) and the Climate Delegated Act (EU 2021/2139).

The TCFD section is reported according to The Companies (Strategic Report) (Climate-related Financial Disclosure) Regulations 2022.

Further information pertaining to the Selected Information have been included in the Sustainability Data Summary 2022 available from https://www.astrazeneca.com/Sustainability/resources.html which should be read alongside the Selected Information included in the Report. This relates to the following sections of the Report: Access to Healthcare, Environmental Protection, Ethics and Transparency, and GHG Reporting under Sustainability Supplementary Information.

Limitations and Exclusions

Excluded from the scope of our work is the verification of information relating to:

- Any percentage progress reported against previous years' performance, such as but not limited to progress against restated 2015 baselines;
- Data for the Healthy Lung programme for 2021 and 2022 which feeds into the number of "healthcare workers trained since 2010" and the reported millions of "people reached through Access to Healthcare programmes";
- With respect to the EU Taxonomy section of the Report, our verification of what AstraZeneca is reporting as eligible activities for 2021 and 2022 does not extend to plans to ensure eligible activities are aligned in the future;
- Activities outside the defined verification period;
- Positional statements (expressions of opinion, belief, aim or future intention by AstraZeneca) and statements of future commitment;
- Financial data taken from the Report and in some cases feeding into the calculation of Selected Information as these are audited by an external financial auditor. This includes but is not limited to any statements relating to production, sales, revenue and financial investments, such as Capex and Opex;
- Other information included in the Report other than scope defined above.

The following limitations should be noted:

- This limited assurance engagement relies on a risk based selected sample of sustainability data and the associated limitations that this entails.
- The reliability of the reported data is dependent on the accuracy of data collection and monitoring arrangements at site level, and it should be noted that not all the Selected Information was sampled at site level as part of this assurance.
- This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

Responsibilities

The preparation and presentation of the Selected Information in the Report is the sole responsibility of the management of AstraZeneca.

Bureau Veritas was not involved in the drafting of the Report. Our responsibilities were to:

- Obtain limited assurance about whether the Selected Information has been appropriately and accurately prepared;
- Form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- Report our conclusions to the Directors of AstraZeneca.

Assessment Standard

We performed our work to a limited level of assurance in accordance with International Standard on Assurance Engagements (ISAE) 3000 Revised, Assurance Engagements Other than Audits or Reviews of Historical Financial Information (effective for assurance reports dated on or after December 15, 2015), issued by the International Auditing and Assurance Standards Board.

Summary of work performed

As part of its independent verification, Bureau Veritas undertook the following activities:

1. Conducted interviews with relevant personnel of AstraZeneca at both Corporate and site level;
2. Carried out four virtual site audits, at the following sites: Gaithersburg – US, North Ryde – Australia, Snäckviken – Sweden, Wuxi – China. We also carried out one physical site visit at 2 Pancras Square, UK. Sites were selected through a risk-based approach following discussion with Bureau Veritas and AstraZeneca, with consideration of contribution to assured data, geographical distribution and type of operations;
3. Reviewed the data collection and consolidation processes used to compile the Selected Information, including assessing assumptions made, the data scope, and reporting boundaries;
4. Agreed a selection of the Selected Information to the corresponding source documentation;
5. Reviewed additional documentary evidence provided by AstraZeneca;
6. Reperformed a selection of aggregation calculations of the Selected Information;
7. Assessed the disclosure and presentation of the Selected Information to ensure consistency with assured information.

A 5% materiality threshold was applied to the assurance of the quantitative Selected Information.

It should be noted that the procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

Conclusion

On the basis of our methodology and the activities and limitations described above, nothing has come to our attention to indicate that the Selected Information is not fairly stated in all material respects. However, the following should be noted:

- AstraZeneca applied a $5m threshold at a project or activity level in aggregating information for analysis used to determine the percentage of Capex and Opex eligible activities under the EU Taxonomy, with activities below this threshold classified as not eligible. Whilst this approach reduces the activities and percentages reported as eligible, it is not considered to result in a material misstatement.

Statement of Independence, Integrity and Competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 190 years history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes.

Bureau Veritas operates a certified[1] Quality Management System which complies with the requirements of ISO 9001:2015, and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards, quality reviews and applicable legal and regulatory requirements which we consider to be equivalent to ISQM 1 & 2[2].

[1] Certificate available on request

[2] International Standard on Quality Management 1 (Previously International Standard on Quality Control 1) & International Standard on Quality Management 2

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)[3], across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities. We consider this to be equivalent to the requirements of the IESBA code[4]. The assurance team for this work does not have any involvement in any other Bureau Veritas projects with AstraZeneca.

Bureau Veritas UK Limited

Registered in England & Wales, Company Number: 1758622
Registered Office: Suite 206 Fort Dunlop, Fort Parkway, Birmingham, B24 9FD

London

7 February 2023

REF: 15975612_AR_v1.0

[3] International Federation of Inspection Agencies – Compliance Code – Third Edition
[4] Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants